Standout Papers
- Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. (1997)
Citation Impact
Citing Papers
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
2007 Standout
Characterization of MicroRNA Expression Levels and Their Biological Correlates in Human Cancer Cell Lines
2007 StandoutNobel
Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation
2012 Science
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
2006 StandoutScience
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
2004 StandoutScience
EglN2 associates with the NRF 1‐ PGC 1α complex and controls mitochondrial function in breast cancer
2015 StandoutNobel
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression
1997
P21-dependent G1arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228
2000
Mismatch Repair-dependent Iterative Excision at Irreparable O6-Methylguanine Lesions in Human Nuclear Extracts
2006 StandoutNobel
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts
1999
A gene expression database for the molecular pharmacology of cancer
2000 Nobel
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
2016
β-Arrestin Is Crucial for Ubiquitination and Down-regulation of the Insulin-like Growth Factor-1 Receptor by Acting as Adaptor for the MDM2 E3 Ligase
2005 StandoutNobel
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
1999
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
2005 StandoutNature
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
2008
A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response
2010 Standout
Molecular mechanisms of drug resistance
2005
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon Cancer
2001
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair
2002
Molecular mechanisms of cisplatin resistance
2011 Standout
<i>TP53</i> Status and Response to Chemotherapy in Breast Cancer
2008
Epithelial–mesenchymal transitions in tumour progression
2002 Standout
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Preclinical Perspectives on Platinum Resistance
2000
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
1999
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
1999 StandoutNatureNobel
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Apoptosis
2002 Standout
A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines 1 1Edited by A. R. Fersht
2000
Clinical trials of p-glycoprotein reversal in solid tumours
1996
Determination of microsatellite instability,p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: Relationship with response to 5-fluorouracil and survival
2001
Cell-cycle dysregulation and anticancer therapy
2003
Ferredoxin reductase affects p53-dependent, 5-fluorouracil–induced apoptosis in colorectal cancer cells
2001
Functional genomics of UV radiation responses in human cells
2004
Neuroblastoma
2007 Standout
Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison
1998
Clinical implications of p53 mutations
1999
Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis
2001
The basics of epithelial-mesenchymal transition
2009 Standout
β-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle Progression
2007 StandoutNobel
Mechanisms of tolerance to DNA damaging therapeutic drugs
2001
Fundamental Relationships Between the Composition of Pluronic Block Copolymers and Their Hypersensitization Effect in MDR Cancer Cells
1999
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
The genetics of the p53 pathway, apoptosis and cancer therapy
2008
Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA
2015 StandoutNobel
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Biological Consequences of Trinuclear Platinum Complexes: Comparison of [{trans-PtCl(NH3)2}2μ-(trans-Pt(NH3)2(H2N(CH2)6-NH2)2)]4+ (BBR 3464) with Its Noncovalent Congeners
2005
Mechanisms of resistance to cisplatin
2001
Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line
2000
Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance
2014
Chemical and Biological Profiles of Novel Copper(II) Complexes Containing S-Donor Ligands for the Treatment of Cancer
2008
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen
1995 Standout
Karyotypic complexity of the NCI-60 drug-screening panel.
2003
Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line.
2001
Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.
2000
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular Senescence
2003 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Chemistry and Biology of the Tetrahydroisoquinoline Antitumor Antibiotics
2002 Standout
Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene
2004
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
2003 Standout
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells
1998
Mechanism of Pluronic Effect on P-Glycoprotein Efflux System in Blood-Brain Barrier: Contributions of Energy Depletion and Membrane Fluidization
2001
Target-Oriented and Diversity-Oriented Organic Synthesis in Drug Discovery
2000 StandoutScience
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.
1999
Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS
1994 StandoutNobel
A multidrug resistance transporter from human MCF-7 breast cancer cells
1998 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833
1999
Diversity Oriented Clicking (DOC): Divergent Synthesis of SuFExable Pharmacophores from 2‐Substituted‐Alkynyl‐1‐Sulfonyl Fluoride (SASF) Hubs
2020 StandoutNobel
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743
1999
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
1999
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers
2005
A new resistance mechanism to cisplatin?
2000
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Next generation diversity-oriented synthesis: a paradigm shift from chemical diversity to biological diversity
2018
Isolation and Synthesis of Biologically Active Carbazole Alkaloids
2002 Standout
The two faces of transforming growth factor β in carcinogenesis
2003 Standout
Works of A Monks being referenced
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
1994
Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
1995
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
1997 StandoutNobel
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
1992